A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

PHASE2UnknownINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2015

Conditions
Essential Hypertension
Interventions
DRUG

Amlodipine 5mg

Daily oral administration for 8 weeks

DRUG

Amlodipine 10mg

Daily oral administration for 8 weeks

DRUG

Candesartan Cilexetil 8mg

Daily oral administration for 8 weeks

DRUG

Candesartan cilexetil 16mg

Daily oral administration for 8 weeks

Trial Locations (20)

Unknown

RECRUITING

Seoul National University Bundang Hospital, Bundang

RECRUITING

Dong-A University Hospital, Busan

RECRUITING

Yeungnam University Medical Center, Daegu

RECRUITING

Konyang University Hospital, Daejeon

RECRUITING

Chonnam National University Hospital, Gwangju

RECRUITING

Inje University Ilsan Paik Hospital, Ilsan

RECRUITING

Inha University Hospital, Incheon

RECRUITING

Hallym University Sacred Heart hospital, Kyungki-do

RECRUITING

Inje University Haeundae Baik Hospital, Pusan

RECRUITING

Pusan National University Hospital, Pusan

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Ewha Womans University Mokdong Hospital, Seoul

RECRUITING

Korea University Guro Hospital, Seoul

RECRUITING

Seoul Medical Center, Seoul

RECRUITING

Seoul St. Mary's hospital, Seoul

RECRUITING

Severance Hospital, Seoul

RECRUITING

Soonchunhyang University Hospital, Seoul

RECRUITING

Yonsei University Gangnam Severance Hospital, Seoul

RECRUITING

Ajou University Hospital, Suwon

RECRUITING

Wonju Severance Christian Hospital, Wŏnju

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY